Publication Name	World Journal of Hepatology
Manuscript ID	87082
Country	Romania

Received	2023-07-23 09:39
Peer-Review Started	2023-07-23 09:42
To Make the First Decision
Return for Revision	2023-09-15 23:44
Revised	2023-10-23 09:04
Second Decision	2023-11-03 09:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-11-09 07:20
Articles in Press	2023-11-09 07:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-11-09 13:20
Publish the Manuscript Online	2023-11-24 06:10

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib
Manuscript Source	Invited Manuscript
All Author List	Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla and Mihnea-Alexandru Găman
Funding Agency and Grant Number
Corresponding Author	Mihnea-Alexandru Găman, Doctor, MD, PhD, Doctor, Research Fellow, Researcher, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, Bucharest 050474, Romania. mihneagaman@yahoo.com
Key Words	Ruxolitinib; Myeloproliferative neoplasms; Hepatitis B; Polycythemia vera; Myelofibrosis; JAK inhibitor
Core Tip	The JAK inhibitor ruxolitinib has been approved for the treatment of classical Philadelphia-negative myeloproliferative neoplasms (MPNs), i.e., polycythemia vera, essential thrombocythemia and primary/secondary myelofibrosis. However, its use has been associated with a potential risk of opportunistic infections, including hepatitis B reactivation. Herein, we briefly overview the association between ruxolitinib treatment in MPNs and hepatitis B reactivation.
Publish Date	2023-11-24 06:10
Citation	Adesola AA, Cozma MA, Chen YF, Srichawla BS, Găman MA. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World J Hepatol 2023; 15(11): 1188-1195
URL	https://www.wjgnet.com/1948-5182/full/v15/i11/1188.htm
DOI	https://dx.doi.org/10.4254/wjh.v15.i11.1188

Full Article (PDF)	WJH-15-1188-with-cover.pdf
Full Article (Word)	WJH-15-1188.docx
Manuscript File	87082_Auto_Edited-LJH-JLW.docx
Answering Reviewers	87082-Answering reviewers.pdf
Audio Core Tip	87082-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	87082-Conflict-of-interest statement.pdf
Copyright License Agreement	87082-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	87082-Grant application form(s).pdf
Peer-review Report	87082-Peer-review(s).pdf
Scientific Misconduct Check	87082-Bing-Liu JH-2.png
Scientific Misconduct Check	87082-CrossCheck.png
Scientific Editor Work List	87082-Scientific editor work list.pdf